Senti Bio Spins Off Lead Asset SENTI-202 to Celadon Affiliate; Stockholders Receive CVRs Worth Up to $60M
SNTI sits 24% above its 52-week low of $0.77 on light trading volume (0.3× avg).
Summary
Senti Biosciences is spinning off its lead cancer therapy, SENTI-202, to a Celadon-controlled private company. Stockholders receive CVRs worth up to $60M in future milestone payments. The remaining public company will focus on early-stage gene therapy programs.
Key Events · M&A and Partnerships · SNTI
-
Merger/Spin-Off Announced
Senti signed a definitive agreement to sell its gene-circuit assets, including SENTI-202, to a Celadon affiliate. Stockholders will receive CVRs entitling them to up to $60M in milestone payments.
-
CVR Milestone Structure
CVRs pay $10M upon BLA filing/acceptance, $20M upon FDA approval, and $30M upon $200M cumulative net sales of SENTI-202, all within 7 years.
-
Retained Business Focus
Post-closing, Senti will advance early-stage Regulator Dial programs for Rett syndrome and armored TIL therapies, retaining limited cash and public company costs.
-
Near-Term Funding Secured
Celadon committed $6M in additional convertible notes or ATM proceeds to fund operations through the expected Q3 2026 closing.
Analysis · SNTI · Life Sciences
Senti Biosciences is splitting in two. The lead clinical asset, SENTI-202, along with other gene-circuit programs, is being sold to a private company controlled by its largest shareholder, Celadon Partners. In return, Senti stockholders will receive contingent value rights (CVRs) that could pay up to $60 million if SENTI-202 achieves regulatory and sales milestones. The remaining public company will focus on early-stage controllable gene and cell therapies using its Regulator Dial platform. To keep operations funded through closing, expected in Q3 2026, the deal includes $6 million in near-term financing from Celadon. With only $6.5 million in cash at June 30 and a going-concern warning already in place, this transaction serves as a lifeline while transferring the most advanced asset to a related party. The CVRs are highly speculative—no payments unless milestones are met within seven years—and the majority-of-the-minority vote requirement gives unaffiliated stockholders a say. A $2.5 million termination fee and no-shop clause limit alternatives, though the board can still consider superior proposals. For a micro-cap biotech on the brink, this is a thesis-altering event.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 42% of the 419 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNTI was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.1M. The 52-week trading range was $0.77 to $2.88. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.